Phio Pharma Q1 net loss $1.8M; PH-762 shows 4 complete responses in Phase 1b trial

Phio Pharmaceuticals Corp.

2025-Q1 EPS reported -$0.41

Cash $13.3M at March 31 vs $5.4M Dec 31; raised $9.2M from offerings and $2.9M from warrant exercises.
Net loss $1.8M for Q1 2025 vs $2.2M in Q1 2024; R&D expenses down 23% to $0.886M.
Phase 1b PH-762: 4 of 9 cSCC patients had pathologic complete response; no dose-limiting toxicities.
4th cohort enrolling; company expects to complete enrollment in Q3 2025.
Sufficient capital to complete treatment phase of Phase 1b trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.